Suspension aerosol formulations
Assignee3M Company
InventorsRobert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
Life of this patent
Estimating the term…
Abstract
Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
Claims24
A pharmaceutical suspension formulation suitable for aerosol administration consisting essentially of:
- (i) particulate drug;
- and
- (ii) 1,1,1,2-tetrafluoroethane as propellant,
- wherein the formulation is further characterized in that it contains no surfactant.
A pharmaceutical formulation consisting essentially of (i) one or more particulate drugs, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation is free of surfactant, the particulate drug or drugs being present in a therapeutically effective amount less than 1.6% w/w relative to the total weight of the formulation and wherein 90% or more of the particles have a diameter of less than 10 microns.
A metered dose inhaler containing a pharmaceutical suspension formulation suitable for aerosol administration, wherein the formulation consists essentially of:
- (i) particulate drug;
- and
- (ii) 1,1,1,2-tetrafluoroethane as propellant,
- wherein the formulation is substantially free of surfactant.
A pharmaceutical suspension formulation suitable for aerosol administration, consisting essentially of:
- a therapeutically effective amount of particulate drug;
- and
- propellant HFC 134a,
- wherein the formulation is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug and wherein the formulation is free of a surfactant.
An aerosol canister containing a formulation suitable for aerosol administration, consisting essentially of:
- particulate drug in an amount sufficient to provide a plurality of therapeutically effective doses of drug;
- and
- propellant HFC 134a,
- wherein the formulation is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug and wherein the formulation is substantially free of surfactant.
A metered dose aerosol canister containing a formulation suitable for aerosol administration, consisting essentially of:
- a therapeutically effective amount of particulate drug in an amount sufficient to provide a plurality of therapeutically effective doses of drug;
- and
- propellant HFC 134a,
- wherein the formulation is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug and wherein the formulation is substantially free of surfactant.
A method of treating a mammal having a condition capable of treatment by inhalation, comprising the step of:
- administering by inhalation a formulation suitable for aerosol administration, wherein the formulation consists essentially of:
- (i) particulate drug;
- and
- (ii) 1,1,1,2-tetrafluoroethane as propellant,
- wherein the formulation is substantially free of surfactant.
A method of treating a mammal having a condition capable of treatment by inhalation, comprising the step of:
- administering by inhalation a formulation suitable for aerosol administration, consisting essentially of:
- a therapeutically effective amount of particulate drug;
- and
- propellant HFC 134a,
- wherein the formulation is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug to the mammal and wherein the formulation contains no surfactant or less than a stabilizing amount of a surfactant.
An aerosol canister containing a formulation suitable for aerosol administration, wherein said formulation consists essentially of:
- particulate drug in an amount sufficient to provide a plurality of therapeutically effective doses of drug;
- and
- propellant HFC 134a,
- wherein the formulation is free of surfactant or contains less than a stabilizing amount of surfactant.
A metered dose aerosol canister containing a formulation suitable for aerosol administration, wherein said formulation consists essentially of:
- particulate drug in an amount sufficient to provide a plurality of therapeutically effective doses of drug;
- and
- propellant HFC 134a,
- wherein the formulation is free of surfactant or contains less than a stabilizing amount of surfactant.
A method of treating a mammal having a condition capable of treatment by inhalation, comprising:
- administering by inhalation a formulation consisting essentially of particulate drug in an amount sufficient to provide a plurality of therapeutically effective doses of drug;
- and
- propellant HFC 134a,
- wherein the formulation is free of surfactant or contains less than a stabilizing amount of surfactant.
Dependencies are inferred from the claim text.